How to buy Onconova Therapeutics stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Onconova Therapeutics stock

Own Onconova Therapeutics stock in just a few minutes.

Onconova Therapeutics, Inc is a biotechnology business based in the US. Onconova Therapeutics shares (ONTX) are listed on the NASDAQ and all prices are listed in US Dollars. Onconova Therapeutics employs 11 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Onconova Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ONTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Onconova Therapeutics share price

Use our graph to track the performance of ONTX stocks over time.

Onconova Therapeutics shares at a glance

Information last updated 2021-04-15.
52-week range$0.19 - $1.87
50-day moving average $1.04
200-day moving average $0.65
Wall St. target price$2.10
PE ratio 0.8266
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.81

Buy Onconova Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Onconova Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Onconova Therapeutics under- or over-valued?

Valuing Onconova Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Onconova Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Onconova Therapeutics's P/E ratio

Onconova Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Onconova Therapeutics shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Onconova Therapeutics financials

Revenue TTM $231,000
Gross profit TTM $231,000
Return on assets TTM -71.56%
Return on equity TTM -283.48%
Profit margin 0%
Book value $0.03
Market capitalisation $149.1 million

TTM: trailing 12 months

Shorting Onconova Therapeutics shares

There are currently 10.2 million Onconova Therapeutics shares held short by investors – that's known as Onconova Therapeutics's "short interest". This figure is 12.4% down from 11.6 million last month.

There are a few different ways that this level of interest in shorting Onconova Therapeutics shares can be evaluated.

Onconova Therapeutics's "short interest ratio" (SIR)

Onconova Therapeutics's "short interest ratio" (SIR) is the quantity of Onconova Therapeutics shares currently shorted divided by the average quantity of Onconova Therapeutics shares traded daily (recently around 23.7 million). Onconova Therapeutics's SIR currently stands at 0.43. In other words for every 100,000 Onconova Therapeutics shares traded daily on the market, roughly 430 shares are currently held short.

However Onconova Therapeutics's short interest can also be evaluated against the total number of Onconova Therapeutics shares, or, against the total number of tradable Onconova Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Onconova Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Onconova Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0432% of the tradable shares (for every 100,000 tradable Onconova Therapeutics shares, roughly 43 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Onconova Therapeutics.

Find out more about how you can short Onconova Therapeutics stock.

Onconova Therapeutics share dividends

We're not expecting Onconova Therapeutics to pay a dividend over the next 12 months.

Have Onconova Therapeutics's shares ever split?

Onconova Therapeutics's shares were split on a 1:15 basis on 25 September 2018. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Onconova Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Onconova Therapeutics shares which in turn could have impacted Onconova Therapeutics's share price.

Onconova Therapeutics share price volatility

Over the last 12 months, Onconova Therapeutics's shares have ranged in value from as little as $0.19 up to $1.87. A popular way to gauge a stock's volatility is its "beta".

ONTX.US volatility(beta: 1.76)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Onconova Therapeutics's is 1.7612. This would suggest that Onconova Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Onconova Therapeutics overview

Onconova Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site